Xconomy National

Archives

by in
Entry Author Date Location
Dendreon Names John Johnson CEO After Volatile Year Arlene Weintraub 02/01/12 Seattle
Dendreon Surprises With $82M in Fourth Quarter Sales, Stock Booms Luke Timmerman 01/05/12 Seattle
Dendreon Pulls In $125M By Selling Royalty Slice of Merck’s Hepatitis C Drug Luke Timmerman 12/06/11 Seattle
Medivation, Astellas Prostate Cancer Drug Helps Men Live Longer; Shares Skyrocket Luke Timmerman 11/03/11 San Francisco
Dendreon Shares Tank Again, Elias Joins Gates Foundation, Seattle Children’s Gets $50M, & More Seattle-Area Life Sciences News Luke Timmerman 11/03/11 Seattle
Dendreon Edges Past Street Expectations With Third Quarter Provenge Sales, Shares Still Fall Luke Timmerman 11/02/11 Seattle
Chris Henney, the Immunex and Dendreon Mover/Shaker, Makes Biotech Hall of Fame Luke Timmerman 10/17/11 Seattle
Dendreon Concentrates Job Cuts in Manufacturing, but Seattle Feels the Axe Too Luke Timmerman 09/08/11 Seattle
Dendreon Whacks 500 Jobs, 25% of Workforce, After Missing Sales Goal Luke Timmerman 09/08/11 Seattle
Theraclone Sniffs Around for $10M, Dendreon Gets Third Factory OK, Zymeworks’ Big Merck Deal, & More Seattle-Area Life Sciences News Luke Timmerman 09/08/11 Seattle
(Mis)Understanding Drug Discovery: It’s Much Harder Than Rocket Science Stewart Lyman 09/07/11 Seattle
Dendreon Wins FDA OK for Atlanta Provenge Factory, Completing National Network Luke Timmerman 08/26/11 Seattle
Dendreon Adds Ex-ImClone CEO to Board Luke Timmerman 08/22/11 Seattle
Dendreon Wounds Are Self-Inflicted, Not the Start of a Biotech Industry Virus Luke Timmerman 08/08/11 National
An Open Letter to Dendreon’s Chairman Brad Loncar 08/05/11 Seattle
Dendreon Takes Huge Hit, Stock Tanks 60% on Sales Shortfall Luke Timmerman 08/03/11 Seattle
Dendreon Misses Street Expectations, Plans Layoffs, Backs Away from Bullish Forecast Luke Timmerman 08/03/11 Seattle
Stop the M&A Obsession: Biotech Needs More Companies to Stay Independent Luke Timmerman 07/18/11 National
Dendreon, After Yearlong Inquiry, Sways Medicare to Pay for $93,000 Prostate Cancer Drug Luke Timmerman 06/30/11 Seattle
Gates Bets on Computer Drug Discovery, Tachi Yamada Joins Frazier, Dendreon’s LA OK, & More in Seattle-Area Life Sciences News Luke Timmerman 06/30/11 Seattle
Dendreon Gets FDA Nod for New LA Cancer Drug Factory Luke Timmerman 06/29/11 Seattle
Exelixis Zeroes in on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Luke Timmerman 06/06/11 San Francisco
Accelerator’s New Startup, Oncofactor, Seeks to Spark Immune System Fight Against Cancer Luke Timmerman 05/24/11 Seattle
The Resurgence of Gene and Cell Therapy Barrie Carter 05/16/11 Seattle
Kleiner Perkins’ Bet on a Concrete Stomach, The Gates Foundation’s Out-of-the-Box Ideas, & More Seattle-Area Life Sciences News Luke Timmerman 05/05/11 Seattle
Dendreon Gets $28M Revenue in Q1 Luke Timmerman 05/02/11 Seattle
Dendreon Faces Internet-Fueled Shareholder Uprising, Led by a Little Guy in Kansas Luke Timmerman 04/01/11 Seattle
Dendreon Wins Full Reimbursement From Medicare for $93K Prostate Cancer Drug Luke Timmerman 03/30/11 Seattle
Think Obamacare Will Suffocate New Drug Development With Price Controls? Think Again Luke Timmerman 03/21/11 National
Dendreon’s Warhorse, Chief Scientific Officer Dave Urdal, To Retire at Year-End Luke Timmerman 03/11/11 Seattle
Page 1 of 5 next page »
    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.